Ultragenyx Pharmaceutical (RARE) Cash from Investing Activities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash from Investing Activities data on file, last reported at -$49.0 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 140.83% year-over-year to -$49.0 million in Q1 2026; TTM through Mar 2026 was $67.0 million, a 785.66% increase from a year earlier, with the FY2025 full-year figure at $236.0 million, up 1411.11% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$49.0 million, up from -$72.2 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for RARE reached as high as $120.0 million in Q1 2025 and fell as low as -$275.5 million in Q3 2024.
• Historically, Cash from Investing Activities has averaged $2.7 million across 5 years, with a median of $64.3 million in 2023.
• Across the five-year window, Cash from Investing Activities jumped 397.91% in 2023 and tumbled 528.5% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$171.6 million in 2022, then jumped by 37.64% to -$107.0 million in 2023, then jumped by 195.78% to $102.5 million in 2024, then tumbled by 170.48% to -$72.2 million in 2025, then soared by 32.18% to -$49.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$49.0 million in Q1 2026, -$72.2 million in Q4 2025, and $117.2 million in Q3 2025.